The deal will allow Gilead to take on Pionyr’s technology, namely its myeloid-tuning therapy, which rebalances a tumor’s microenvironment to privilege immune-activating cells over immune-suppressing ones. Gilead is focusing on PY314 and PY159, Pionyr’s two preclinical antibodies developed to enhance anti-tumor immunity.
The myeloid-tuning technology exhibits potential to treat patients who are resistant to checkpoint inhibitor therapies.
“The agreement represents important progress as we continue to build out Gilead’s presence in immuno-oncology with innovative and complementary approaches,” Daniel O’Day, Gilead’s CEO, said in a news release.
More articles on pharmacy:
Court invalidates Biogen’s Tecfidera patent
Average pharmacist salaries, by state
Walgreens continues providing vaccinations, implements new safety protocols
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
